Lead Product(s): JTA-004
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase III Product Type: Large molecule
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Funding August 13, 2020
Funding will provide further financial support to Bone Therapeutics, in addition to recent financing, to advance its current pivotal phase III clinical study with the enriched protein solution, JTA-004.
Lead Product(s): Hyaluronic Acid,Plasma proteins,Fast-acting analgesic
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
The JTA-004 phase III study is a controlled, randomized, double-blind trial that will evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20.